H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $140.00 price target on Cytokinetics (NASDAQ: CYTK).The analyst commented: "Cytokinetics ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments